The ability of gefitinib to reduce Aβ-mediated AChE levels and attenuate cognitive impairments supports its potential as an AD treatment, but whether gefitinib directly affects other AD-associated factors (e.g., tau pathology) and its molecular mechanisms of action on AD pathology remain to be clarified. Here, MAPT is linked to Cognitive impairment.